Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
Meredith McCormackRosirene PaczkowskiNoelle N GronroosStephen G NoorduynLydia LeePhani VeerankiMary G JohnsonEmmeline IgboekweKristin Kahle-WrobleskiReynold PanettieriPublished in: Advances in therapy (2024)
Patients with COPD treated with ICS/LABA during baseline, including patients specifically treated with BUD/FORM and those with a history of ≥ 1 exacerbation, had fewer COPD exacerbations and lower COPD-related HCRU after initiating FF/UMEC/VI.
Keyphrases
- chronic obstructive pulmonary disease
- lung function
- newly diagnosed
- end stage renal disease
- ejection fraction
- cystic fibrosis
- chronic kidney disease
- peritoneal dialysis
- adipose tissue
- intensive care unit
- skeletal muscle
- acute respiratory distress syndrome
- extracorporeal membrane oxygenation
- patient reported
- smoking cessation